# Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

> **NCT02191891** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 32 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Xentuzumab
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02191891
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-21
- **Primary completion:** 2018-04-18
- **Final completion:** 2018-04-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191891, "Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02191891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*